Annexon Files Routine 8-K, Confirms Corporate Details
Ticker: ANNX · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1528115
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, administrative, compliance
TL;DR
**Annexon's 8-K is a routine administrative filing, no major news.**
AI Summary
Annexon, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 7, 2024. This filing is a routine update to disclose general corporate information, including its business address at 1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005, and its common stock trading on The Nasdaq Stock Market under the symbol ANNX. For investors, this filing primarily serves as a confirmation of basic company details and compliance with SEC disclosure requirements, without revealing new financial or operational developments that would directly impact stock valuation.
Why It Matters
This filing is a standard procedural update, confirming basic company information and compliance, rather than announcing significant news that would alter investment decisions.
Risk Assessment
Risk Level: low — This 8-K filing contains only administrative information and does not disclose any events that would introduce new risks or uncertainties.
Analyst Insight
Investors should note this is a routine administrative filing and does not contain new material information that would warrant immediate action regarding Annexon, Inc. stock. Continue to monitor for substantive news.
Key Numbers
- $0.001 — par value per share (the nominal value assigned to each share of common stock)
Key Players & Entities
- Annexon, Inc. (company) — the registrant filing the 8-K
- The Nasdaq Stock Market (company) — the exchange where Annexon's common stock is registered
- ANNX (company) — trading symbol for Annexon, Inc.
- January 7, 2024 (date) — date of the earliest event reported
- January 8, 2024 (date) — date the 8-K was filed
- 1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005 (address) — principal executive offices of Annexon, Inc.
- $0.001 (dollar_amount) — par value per share of common stock
FAQ
What is the purpose of this 8-K filing by Annexon, Inc.?
This 8-K filing by Annexon, Inc. is a current report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, primarily serving to disclose general corporate information and confirm compliance with SEC regulations, with the earliest event reported on January 7, 2024.
Where are Annexon, Inc.'s principal executive offices located?
Annexon, Inc.'s principal executive offices are located at 1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005, as stated in the filing.
What is the trading symbol and exchange for Annexon, Inc.'s common stock?
Annexon, Inc.'s common stock trades under the symbol ANNX on The Nasdaq Stock Market, as indicated in the 'Securities registered pursuant to Section 12(b) of the Act' section of the filing.
What is the par value of Annexon, Inc.'s common stock?
The par value of Annexon, Inc.'s common stock is $0.001 per share, as specified under 'Title of each class' in the filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 7, 2024, as stated under 'Date of Report (Date of earliest event reported): January 7, 2024'.
Filing Stats: 659 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2024-01-08 16:09:03
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ANNX The Nasdaq Stock Mar
Filing Documents
- d609684d8k.htm (8-K) — 26KB
- d609684dex991.htm (EX-99.1) — 25KB
- g609684g0108035540065.jpg (GRAPHIC) — 3KB
- 0001193125-24-004387.txt ( ) — 184KB
- annx-20240107.xsd (EX-101.SCH) — 3KB
- annx-20240107_lab.xml (EX-101.LAB) — 18KB
- annx-20240107_pre.xml (EX-101.PRE) — 11KB
- d609684d8k_htm.xml (XML) — 3KB
01
Item 7.01. Regulation FD Disclosure. On January 7, 2024, Annexon, Inc. ("Annexon" or the "Company") issued a press release titled "Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases." A copy of the Company's press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. As announced, management of Annexon will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 2:15 p.m. PT. A live webcast of the presentation will be accessible through the Events & Presentations' section on the Investors page of Annexon's website. An archive of the webcast will be available on Annexon's website for 30 days. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated January 7, 2024, titled "Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases." 104 Cover Page Interactive Data File, formatted in inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 8, 2024 Annexon, Inc. By: /s/ Jennifer Lew Jennifer Lew Executive Vice President and Chief Financial Officer